Galmed Pharmaceuticals Ltd. EOCN
Galmed Pharmaceuticals Ltd. (Nasdaq: EOCN) is an oncology drug developer. Its lead program, Aramchol, is in Phase 2 for Oncology (GI cancers, development being advanced); historically NASH/MASH and fibrosis. Its next catalyst on record is CG-100 (Colospan): Submit real-world data to FDA to support US pivotal study; first device revenue (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CG-100 (Colospan) — Submit real-world data to FDA to support US pivotal study; first device revenue (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Aramchol ARMOR Phase 3 (NASH/fibrosis) - open-label part discontinued 2022; second part not expected to start | NASH/MASH with fibrosis | small molecule | Phase 3 |
| Aramchol (oncology indications; no active trial described) | GI oncology indications outside NASH | small molecule | Phase 2 |
| CG-100 intraluminal bypass device (Colospan; CE marked, US pivotal IDE study ongoing) | Protection of colorectal anastomoses / avoiding diverting stoma | device-combination | NA_NON_THERAPEUTIC |
| Intraoperative colon tissue assessment platform (Colospan) | Colorectal surgery tissue quality | unclear | NA_NON_THERAPEUTIC |
Recent results and decisions
- Sep 10, 2026n/a Galmed Pharmaceuticals rebrands to Eocene Ltd. with new Nasdaq ticker symbol EOCN effective September 10, 2026.
The name change and trading symbol change are expected to become effective on the Nasdaq Capital Market on September 10, 2026.
Filing - Sep 9, 2026n/a Galmed terminates Standby Equity Purchase Agreement with Yorkville after raising $7.3 million through issuance of 437,947 ordinary shares.
The SEPA provided the Company with an equity line of up to $20 million, and as of the date of termination, Galmed raised approximately $7.3 million from the SEPA through the issuance of 437,947 ordinary shares.
Filing - Sep 9, 2026n/a Galmed regained Nasdaq minimum bid price compliance and changes ticker from GLMD to EOCN effective September 10, 2026.
The Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and will continue to be listed and traded on the Nasdaq Capital Market under the new ticker symbol
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.